nach oben

Tipp

New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy

verfasst von: Prof. Dr. Marco Idzko, Sylvia Hartl, Bernd Lamprecht, Matthias Reisinger, Judith Löffler-Ragg, Markus Rauter, Michael Studnicka, Wolfgang Pohl

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2021

Einloggen, um Zugang zu erhalten

Excerpt

Asthma has been recognized as an inflammatory disease, with chronic airway inflammation underlying bronchial hyperresponsiveness and bronchoconstriction [ 1, 2]. Several studies established the presence of increased numbers of inflammatory cells including eosinophils, dendritic cells, type 2 innate lymphoid cells (ILC2), mast cells and lymphocytes in the lung tissue, bronchoalveolar lavage, and sputum from asthmatic patients [ 1‐ 7]. Airway inflammation increases at times of exacerbations and is even present in patients with mild asthma despite a relatively low burden of symptoms [ 8]. …

Vorheriger Artikel New insights and antimicrobial stewardship opportunities in viral pneumonia: five lung ultrasound cases

Nächster Artikel Correction to: Potential association of the prognostic index and survival in patients with p16-positive oropharyngeal squamous cell carcinoma

Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800. PubMedCrossRef

Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360–72. PubMedCrossRef

Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM, et al. Eosinophils, T‑lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol. 1991;88(4):661–74. PubMedCrossRef

Kirby JG, Hargreave FE, Gleich GJ, O’Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis. 1987;136(2):379–83. PubMedCrossRef

Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992;47(1):25–9. PubMedPubMedCentralCrossRef

Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. PubMedPubMedCentralCrossRef

Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. PubMedCrossRef

Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. PubMedCrossRef

Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention (for adults and children older than 5 years). A pocket guide for health professionals update. 2019. https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf.

10.

Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2020. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.

11.

Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev. 2001;4:CD3274.

12.

Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–6. PubMedCrossRef

13.

Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880–4. PubMedPubMedCentralCrossRef

14.

Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995;108(5):1228–34. PubMedCrossRef

15.

Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157–66. PubMedCrossRef

16.

Global Initiative for Asthma – GINA. Archived reports. 2021. https://ginasthma.org/archived-reports/.

17.

Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007;119(4):916–23. PubMedCrossRef

18.

Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83(4):330–3. PubMedPubMedCentralCrossRef

19.

Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. PubMedPubMedCentralCrossRef

20.

Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–6. PubMedCrossRef

21.

Nathan RA, Thompson PJ, Price D, Fabbri LM, Salvi S, González-Díaz S, et al. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract. 2015;3(5):734–742.e5. PubMedCrossRef

22.

Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise asthma and link to symptoms and experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. PubMedPubMedCentralCrossRef

23.

Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66–74. PubMedCrossRef

24.

Braido F, Brusselle G, Guastalla D, Ingrassia E, Nicolini G, Price D, et al. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional AND longitudinal assessment on asthma control (liaison) study. Respir Res. 2016;17(1):51. PubMedPubMedCentralCrossRef

25.

O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50(3):1701103. PubMedCrossRef

26.

Beasley R, Bird G, Harper J, Weatherall M. The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. Eur Respir J. 2018;52(5):1800694. PubMedCrossRef

27.

Lenney W, Milner AD, Hiller EJ. Continuous and intermittent salbutamol tablet administration in asthmatic children. Br J Dis Chest. 1979;73(3):277–81. PubMedCrossRef

28.

Shepherd GL, Hetzel MR, Clark TJ. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest. 1981;75(2):215–7. PubMedCrossRef

29.

Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140(10):802–13. PubMedCrossRef

30.

Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2020;110(6):S322–8. CrossRef

31.

Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β‑agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–7. PubMedCrossRef

32.

Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3 Pt 1):604–10. PubMedCrossRef

33.

Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79(4):653–9. PubMedCrossRef

34.

Gavreau G, Jordana M, Watson RM, Cockroft DW, O’Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 1997;156(6):1738–45. CrossRef

35.

Mitchell EA. Is current treatment increasing asthma mortality and morbidity? Thorax. 1989;44(2):81–4. PubMedPubMedCentralCrossRef

36.

Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–87. PubMedCrossRef

37.

O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–76. PubMedCrossRef

38.

O’Byrne P, Fitzgerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. Eur Respir J. 2018;52(62):OA1680.

39.

Buhl R, Kuna P, Peters MJ, Andersson TL, Naya PI, Peterson S, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13:59. PubMedPubMedCentralCrossRef

40.

Beasley N, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–30. PubMedCrossRef

41.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–28. PubMedCrossRef

42.

Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison TW, et al. ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. Eur Respir J. 2020;55:1901407. PubMedCrossRef

43.

Licskai C, Yang CL, Lemiere C, Ducharme FM, Lougheed MD, Radhakrishnan D, et al. Are the 2019 global initiative for asthma (GINA) strategy recommendations applicable to the Canadian context? Can J Respir Crit Care Sleep Med. 2020;4(1):3–6.

44.

O’Byrne P, Bateman ED, FitzGerald JM, Barnes PJ, Zhong N, Alagappan VKT, et al. Efficacy of as-needed budesonide/formoterol for reducing severe exacerbations in adolescents with mild asthma: pooled subgroup analysis of the SYGMA 1 and 2 trials. Am J Respir Crit Care Med. 2020;201:A7191.

Titel: New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy
verfasst von: Prof. Dr. Marco Idzko
Sylvia Hartl
Bernd Lamprecht
Matthias Reisinger
Judith Löffler-Ragg
Markus Rauter
Michael Studnicka
Wolfgang Pohl
Publikationsdatum: 26.03.2021
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 21-22/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-021-01830-1

Home

Zeitschriften

Zeitungen

Podcast

Gesundheitspolitik

Praxis

Leben

Jobs

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy

Excerpt

Fachgebiete

Subfächer Innere Medizin

Fortbildungen

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 21-22/2021

Veranstaltungstipps

Correction to: Potential association of the prognostic index and survival in patients with p16-positive oropharyngeal squamous cell carcinoma

Chemobrachyradiotherapy and consolidation chemotherapy in treatment of locally advanced cervical cancer

New insights and antimicrobial stewardship opportunities in viral pneumonia: five lung ultrasound cases

Multimodal assessment of disease activity in glioblastoma

Risk factors for nontuberculous mycobacterial pulmonary disease (NTM-PD) in Croatia